688202 Shanghai Medicilon Inc.
- 36.88
- -0.02-0.05%
Shanghai Medicilon Inc. News
Medici (688202): Domestic industry competition is fierce, and overseas expansion of companies is beginning to show results
Medici (688202): Q1 month-on-month improvement and cost reduction results
Medici (688202): Short-term performance is pressured and continued international expansion is expected to bring about performance flexibility
Medici (688202) 2023 Annual Report Review: Increased industry competition puts pressure on performance and preclinical business continues to expand
Medici (688202): Short-term performance under pressure to accumulate long-term development
Medici (688202): Delayed order execution, revenue, and profit are under pressure
Medici (688202): Order delays and performance are temporarily under pressure, overseas development is seeking new growth
Medici (688202): Performance was significantly affected by the cooling of domestic investment and financing and continued to strengthen domestic and foreign market expansion
Medici (688202): Steady revenue growth, fixed increase, energy for medium- to long-term development
Medici (688202): Overseas business is under pressure in the short term and is expected to contribute new momentum
Medici (688202): Performance is affected by weakening domestic and foreign trends, and overseas business is expected to continue to contribute to performance elasticity
Medici (688202) In-depth Report: R&D Continues to Invest in High-Quality Platform Pre-Clinical CRO
Medici (688202) 202A&23Q1 earnings review: profits were under pressure throughout the year, and Q1 rebounded steadily
Medici (688202) Company Information Update Report: Strong Performance, Sufficient New Orders to Establish High Growth in the Future
Medici (688202): Performance growth is in line with expectations, internationalization expansion gradually contributes to performance elasticity
Medici (688202): 2022 Q3 resumes rapid growth and further improves operational efficiency
Medici (688202): New orders increase, sustainable capacity construction accelerates
Medici (688202): Steady growth in H1 operations in 2022, rapid growth in new orders
Medici (688202): New orders are growing rapidly, capacity building is getting better
Medici (688202): Production capacity construction accelerates, high orders continue
Analysis
Price Target
No Data
No Data